XML 80 R62.htm IDEA: XBRL DOCUMENT
v3.20.4

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands | 3 Months Ended |  |
--- | --- | --- | ---
Mar. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($)
Assets: |  |  |
Fair value of assets |  | $ 324,055 | $ 314,270
Liabilities: |  |  |
Contingent consideration payable |  | 25,825 | 22,681
Deferred compensation plan liability |  | 4,078 | 4,419
Fair value of liabilities |  | 29,903 | 27,100
Milestone payment, stock issued as consideration | $ 9,000 |  |
Common Stock |  |  |
Liabilities: |  |  |
Milestone payment, stock issued as consideration | $ 9,300 |  |
ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Callidus |  |  |
Liabilities: |  |  |
Contingent consideration payable |  | $ 25,101 |
ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Callidus | Probability of Milestone Achievement | Minimum |  |  |
Liabilities: |  |  |
Contingent consideration, measurement input |  | 0.75 |
ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Callidus | Probability of Milestone Achievement | Maximum |  |  |
Liabilities: |  |  |
Contingent consideration, measurement input |  | 0.78 |
Convertible Notes | 2016 Convertible Notes |  |  |
Liabilities: |  |  |
Fair value of the debt |  | $ 10,900 |
Commercial paper |  |  |
Assets: |  |  |
Fair value of assets |  | 217,095 | 73,710
Asset-backed securities |  |  |
Assets: |  |  |
Fair value of assets |  | 9,438 | 77,810
Corporate debt securities |  |  |
Assets: |  |  |
Fair value of assets |  | 39,513 | 145,991
U.S. government agency bonds |  |  |
Assets: |  |  |
Fair value of assets |  | 53,582 | 11,991
Money market |  |  |
Assets: |  |  |
Fair value of assets |  | 4,427 | 4,768
Level 2 |  |  |
Assets: |  |  |
Fair value of assets |  | 324,055 | 314,270
Liabilities: |  |  |
Contingent consideration payable |  | 0 | 0
Deferred compensation plan liability |  | 4,078 | 4,419
Fair value of liabilities |  | 4,078 | 4,419
Level 2 | Commercial paper |  |  |
Assets: |  |  |
Fair value of assets |  | 217,095 | 73,710
Level 2 | Asset-backed securities |  |  |
Assets: |  |  |
Fair value of assets |  | 9,438 | 77,810
Level 2 | Corporate debt securities |  |  |
Assets: |  |  |
Fair value of assets |  | 39,513 | 145,991
Level 2 | U.S. government agency bonds |  |  |
Assets: |  |  |
Fair value of assets |  | 53,582 | 11,991
Level 2 | Money market |  |  |
Assets: |  |  |
Fair value of assets |  | 4,427 | 4,768
Level 3 |  |  |
Liabilities: |  |  |
Contingent consideration payable |  | 25,825 | 22,681
Deferred compensation plan liability |  | 0 | 0
Fair value of liabilities |  | $ 25,825 | $ 22,681
Level 3 | ATB-200 Pompe Program | Clinical and Regulatory Approval Milestones | Probability Weighted Discounted Cash Flow | Callidus | Discount Rate |  |  |
Liabilities: |  |  |
Contingent consideration, measurement input |  | 0.075 |

X
- Definition Contingent Consideration, Measurement Input + References No definition available. + Details
Name: | fold_ContingentConsiderationMeasurementInput
Namespace Prefix: | fold_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone Payment, Stock Issued As Consideration + References No definition available. + Details
Name: | fold_MilestonePaymentStockIssuedAsConsideration
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + References No definition available. + Details
Name: | us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements. + References No definition available. + Details
Name: | us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |